✓ Translated by DotMD AI Clinical Council Source: Journal of Korean medical science • Phase III Randomized Trial
Verify Primary Source: NIH PubMed PMID #41807028 ↗

Phase III Randomized Trial: Randomized, Double-Blind, Multicenter, Phase 3 Study of AG NPP709 Compared With Ivy Leaf Extract in Patients With Acute or Chronic Respiratory Symptoms (N = 118)

Original Paper Title: “Randomized, Double-Blind, Multicenter, Phase 3 Study of AG NPP709 Compared With Ivy Leaf Extract in Patients With Acute or Chronic Respiratory Symptoms”

Elena Rostova (AI Quant) Rigor Score
88 / 100
Sample Size (Participants)
N = 118
Evidence Classification
Phase III Randomized Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • AG NPP709 was non-inferior to ivy leaf extract and had an acceptable safety profile. AG NPP709 could be an alternative treatment option for alleviating the symptoms associated with acute URI and chronic bronchitis.
  • Study Design & Sample: Phase III Randomized Trial published in Journal of Korean medical science (N = 118 human participants).
  • Biostatistical Rigor Score: 88/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Journal of Korean medical science (2026), this phase iii randomized trial evaluating 118 human participants investigated: AG NPP709, formulated with extracts of ivy leaves and Coptis chinensis rhizomes, has antitussive and expectorant effects in preclinical rodent studies. Key clinical takeaway: AG NPP709 was non-inferior to ivy leaf extract and had an acceptable safety profile. AG NPP709 could be an alternative treatment option for alleviating the symptoms associated with acute URI and chronic bronchitis.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Journal of Korean medical science, 2026-03-09; N = 118; Rigor 88/100): AG NPP709 was non-inferior to ivy leaf extract and had an acceptable safety profile. AG NPP709 could be an alternative treatment option for alleviating the symptoms associated with acute URI and chronic bronchitis.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Condition: long-covid → Condition: lung-diseases →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 41807028: Phase III Randomized Trial: Randomized, Double-Blind, Multicenter, Phase 3 Study of AG NPP709 Compared With Ivy Leaf Extract in Patients With Acute or Chronic Respiratory Symptoms (N = 118)

3 of 3 Free Questions Remaining